A download link will be emailed after check out.
Mvasi is a biosimilar medicine to Avastin, and a treatment option in combination with chemotherapy, for patients with metastatic bowel cancer (mCRC).
A biosimilar medicine is a very similar version of an already-approved biological medicine, in terms of its characteristics, quality, safety and efficacy.
A biosimilar medicine is not considered a generic medicine, as it is virtually impossible to make an exact copy of a living organism. However, much like generics, biosimilar medicines are also based on original medicines that have reached the end of their patents.
